OSE's Lusvertikimab Showcase Comes With a Four-Month Cash Clock

On September 2, OSE Immunotherapeutics (Euronext Paris: OSE) will host a webcast dedicated to lusvertikimab, its lead inflammatory-bowel-disease drug, putting it in front of two respected IBD specialists — Laurent Peyrin-Biroulet of Nancy University Hospital and Maia Kayal of Mount Sinai — plus the CEO and chief scientific officer — and take questions. Bulls will read the event as a promising Phase 2 program being showcased to extract a partnership. Bears will read it as the warm-up act for a capital raise at a company whose cash runs out around year-end. Both camps can agree on the drug, the balance sheet, and the stock — roughly €3.30, worth about €80 million. The disagreement is what this webcast is actually selling.

The record both sides should sign

These are the facts neither camp can dodge, as of late August 2026:

• The stock. About €3.30, down roughly 39% year to date and about 57% below its 52-week high of €7.70. Market value around €80 million on 24,226,111 shares as of July 31, 2026.
• The money.€17.0 million of gross cash at March 31, 2026, plus a bridge-equity facility with IRIS Capital worth up to about €19.3 million over 24 months (€2 million drawn in June 2026). Management guidance: runway to the end of December 2026. Debt of about €32 million, including roughly €16 million owed to the European Investment Bank, with about €7 million of that repayable in July 2026 — figures from a June 2026 Edison research note.
• The burn. Fiscal 2025 net loss of €37.7 million on €2.6 million of revenue, versus €69.9 million of revenue in 2024, a year inflated by AbbVie's $48 million upfront for a different asset (OSE-230). R&D spending hit €33.9 million, and operating cash use was about €34 million.
• The drug. In the CoTikiS Phase 2 trial in moderate-to-severe ulcerative colitis (136 patients), lusvertikimab beat placebo on the primary endpoint at week 10. Clinical remission was 16% versus 4% for placebo; endoscopic remission 25% versus 13%; endoscopic improvement 32% versus 13%. Safety was clean apart from a transient drop in lymphocytes.
• The plan. Partner the UC program after subcutaneous-formulation bioequivalence data; start a chronic pouchitis Phase 2a in the second half of 2026 and a hidradenitis suppurativa proof-of-concept — both, per the company's own phrasing, "subject to financing."
• The next checkpoint. First-half 2026 results, with a fresh cash position, arrive September 28.

Round 1 — The drug: is the signal real?

Bull's best punch. Lusvertikimab is described as a first-in-class IL-7 receptor antagonist — it blocks a pathway those other drugs don't touch. IL-7 drives the effector T cells that sustain gut inflammation, and that pathway is overactive precisely in patients who stop responding to today's biologics — roughly half of patients do not achieve clinical remission on the newest agents. It also operates in an ulcerative-colitis market worth more than $11 billion a year. A clean safety profile in a field scarred by small-molecule warnings, a positive primary endpoint, and a meaningful dose of external validation — the September 2 webcast brings in two prominent IBD specialists — say the asset is taken seriously by people who actually treat the disease.

Bear's answer. The headline number flatters. "16% versus 4%" is a pooled, rounded reading; per the ECCO 2025 presentation of the data, the clinical-remission comparison did not reach statistical significance (p = 0.066), and neither did endoscopic remission (p = 0.120). Only endoscopic improvement crossed the line, at 32% versus 13% (p = 0.027). In the same patient population, the newest approved drugs do better in induction: risankizumab posted 20.3% versus 6.2% clinical remission at week 12, and guselkumab reached 27.6% in a separate Phase 3 trial. Lusvertikimab is also delivered intravenously in a market that has migrated to subcutaneous and oral dosing, and its own dose response is flat — the 850 mg arm looked no better than the 450 mg arm.

Bull's reply. CoTikiS enrolled a harder group — roughly 40% had already failed a biologic — and induction remission is the wrong lens for a drug built for the refractory and combination niche, not for head-to-head supremacy against IL-23s. The mechanism, not the 16%, is the asset.

Winner of the round: the bull, narrowly, on substance. The drug is real, novel, safe, and partnerable. But the bear just found the scar: two of the four named endpoints missed the significance bar, and the absolute effect is below the modern standard of care. That scar matters less for science and more for the price a future partner writes.

Round 2 — The money: can OSE pay to find out?

Bear's best punch. This round decides the stock. The balance sheet gives the company until roughly the end of 2026 — about four months — during which it must burn roughly €8.5 million a quarter and repay European Investment Bank debt, then it needs more money. The bridge facility is not optionality; per the company's May announcement, it is an ATM-style instrument priced at 95% of the lowest daily volume-weighted average price in the prior three days. Drawing it keeps the lights on by selling shares at a 5% haircut to a counterparty, on top of the ~€32 million already owed. A research note from Edison, which covers the company, estimates OSE will need up to €90 million of additional funding through fiscal 2029. And the last "anchor" partner left: AbbVie, which paid $48 million upfront in 2024, reverted Phase 1 duties on OSE-230 in December and paused that program in 2026 — which is also why reported revenue collapsed from €69.9 million in 2024 to €2.6 million in 2025.

Bull's answer. The modular plan is designed precisely for this constraint. Chronic pouchitis is a rare-disease path — roughly 45,000 patients across the EU, North America and Japan, with only one EMA-approved therapy and none FDA-approved — so trials are small, fast, and cheap, and the route to market is quicker. HS, at roughly 9.5 million patients, offers a quick proof-of-concept in a big dermatology market. UC itself is the partnering prize: a modest upfront for a Phase 2-positive UC asset can run into the tens of millions — enough to exceed the company's entire current market value. The IRIS facility was the explicit "first step" of a global financing strategy; the webcast, in that reading, is step two.

Bear's reply. Every one of those trial starts is the company's own words — "subject to financing" — and the UC partnership awaits bioequivalence data that have not been published. The bull's case rests entirely on a transaction that has not been announced; the bear's case requires only that the transaction fail to arrive before the money runs out. One camp is betting on a headline, the other on arithmetic.

Winner of the round: the bear, and by the widest margin of the fight. The bull's punch is a hope; the bear's is a spreadsheet.

Round 3 — What does the price already demand?

Now make both stories pay rent. At €3.30 the market is putting roughly €90 million of enterprise value on the whole company once you net about €19 million of cash against €32 million of debt. For that money a buyer gets a Phase 2-positive, novel-mechanism IBD asset, a Phase 3 lung-cancer vaccine (Tedopi), and two partner hand-me-downs. That is not a price demanding perfection; it is a price demanding little more than survival.

The asymmetry is real and it cuts both ways. If a partner writes even a mid-double-digit-million-euro upfront for UC alone, the press release could be worth more than the current equity. That is the bull's entire case, and it is not crazy. But the market is also telling you it has watched this before: the stock fell 57% from its high because investors learned to discount the financing before the news. A June 2026 Edison note values the equity at €16.60 a share — five times the market — and also says the company needs up to €90 million it does not have. A fivefold fair-value gap with an empty treasury is not a discount; it is the market pricing in the dilution and the execution risk between here and any deal.

The ruling

The scientific case goes to the bulls; the stock call, at this price, goes to the bears through at least the end of the cash window. Lusvertikimab looks like a genuine asset with a credible path — but a clinical-stage micro-cap whose next trial starts are "subject to financing," whose cash reaches December, and whose next meaningful lusvertikimab catalysts are a partnership and a formulation readout that do not exist yet, is a coordination problem, not a data story. The September 2 webcast is a piece of the financing machine, and watching it for signs of efficacy would be watching the wrong part of the screen. Watch it for what management signals about timing: partnership language, financing hints, and what the CSO says about the subcutaneous timeline.

The ruling flips if, by the end of 2026, any one of these lands: a UC partnership or out-license with an upfront meaningful enough to cover a year of burn; a strategic, non-discounted equity investment (the US/European institutional money they say they are courting); or a financed pouchitis trial start. The first checkpoint is September 28, when H1 results and the cash balance tell you whether the clock is really as long as it looks. The earliest confirming signal for the bear case is continued silent drawdowns on the IRIS facility — shares sold at a 5% discount with no deal announced — or the pouchitis start slipping into 2027. One more lever worth watching: Tedopi's Phase 3 futility readout, which Edison's June note places in the current quarter. If that program stops, lusvertikimab becomes the whole story, and the financing math gets harder, not easier. One practical gate for a US retail investor: OSE is an €80-million micro-cap listed on Euronext Paris and priced in euros, so most US accounts need a broker that handles European listings.

Watch the webcast for the clock, not the applause.